Total Payments
$2,716
2024 Payments
$701.17
Companies
27
Transactions
173
Medicare Patients
1,394
Medicare Billing
$232,488
Payment Breakdown by Category
Food & Beverage$2,683 (98.8%)
Education$32.27 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,683 | 172 | 98.8% |
| Education | $32.27 | 1 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $469.90 | 23 | $0 (2024) |
| Novo Nordisk Inc | $462.03 | 58 | $0 (2024) |
| Amgen Inc. | $254.27 | 16 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $208.34 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $159.86 | 8 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $143.92 | 7 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $118.64 | 6 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $106.11 | 5 | $0 (2024) |
| Horizon Therapeutics plc | $97.72 | 5 | $0 (2023) |
| ABBVIE INC. | $72.14 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $701.17 | 35 | Lilly USA, LLC ($151.11) |
| 2023 | $514.35 | 25 | Lilly USA, LLC ($89.57) |
| 2022 | $794.40 | 57 | Novo Nordisk Inc ($156.09) |
| 2021 | $705.79 | 56 | Novo Nordisk Inc ($199.14) |
All Payment Transactions
173 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Obesity | ||||||
| 12/03/2024 | CeQur Corporation | CeQur Simplicity (Device) | Food and Beverage | Cash or cash equivalent | $25.98 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $8.52 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Biological | ||||||
| 11/12/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $23.59 | General |
| Category: Endocrinology | ||||||
| 10/29/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: Bone Health | ||||||
| 10/29/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Diabetes | ||||||
| 10/22/2024 | Novo Nordisk Inc | Saxenda (Drug), Wegovy | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Obesity | ||||||
| 10/15/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Bone Health | ||||||
| 10/08/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $11.62 | General |
| Category: Bone Health | ||||||
| 09/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $30.67 | General |
| Category: Cardiology | ||||||
| 08/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.44 | General |
| Category: DIABETES | ||||||
| 08/20/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: Inflammation/Rare Disease | ||||||
| 08/13/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: IMMUNOLOGY | ||||||
| 08/08/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: Diabetes | ||||||
| 08/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SYNJARDY (Drug), TRADJENTA, JARDIANCE | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: DIABETES | ||||||
| 07/23/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Endocrinology | ||||||
| 07/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: Diabetes | ||||||
| 07/09/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Biological | ||||||
| 06/25/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Bone Health | ||||||
| 06/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.05 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Obesity | ||||||
| 05/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Cardio-renal | ||||||
| 05/28/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $7.26 | General |
| Category: Bone Health | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 281 | 1,205 | $171,460 | $41,858 |
| 2022 | 6 | 362 | 2,469 | $238,685 | $68,454 |
| 2021 | 6 | 435 | 2,710 | $207,103 | $71,515 |
| 2020 | 5 | 316 | 2,246 | $142,422 | $50,661 |
Total Patients
1,394
Total Services
8,630
Medicare Billing
$232,488
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 138 | 230 | $96,600 | $17,924 | 18.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 780 | $27,300 | $14,374 | 52.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 98 | 159 | $39,750 | $8,244 | 20.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 23 | $6,900 | $1,188 | 17.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 13 | $910.00 | $128.18 | 14.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 26 | 1,920 | $67,200 | $32,930 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 158 | 269 | $107,560 | $22,153 | 20.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 104 | 196 | $49,000 | $10,424 | 21.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 33 | $9,600 | $1,945 | 20.3% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 16 | 19 | $3,135 | $676.09 | 21.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 26 | 32 | $2,190 | $325.33 | 14.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 29 | 2,160 | $56,700 | $35,552 | 62.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 141 | 206 | $68,513 | $17,918 | 26.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 115 | 170 | $42,500 | $11,070 | 26.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 111 | 129 | $32,400 | $5,579 | 17.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 11 | $4,950 | $1,047 | 21.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 28 | 34 | $2,040 | $348.84 | 17.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 30 | 1,860 | $48,360 | $29,375 | 60.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 120 | 184 | $58,328 | $12,593 | 21.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 101 | 121 | $30,250 | $6,070 | 20.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 36 | 52 | $3,744 | $2,327 | 62.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 29 | 29 | $1,740 | $296.62 | 17.0% |
About Nadine Daou, NP-C
Nadine Daou, NP-C is a Nurse Practitioner healthcare provider based in Newburyport, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2016. The National Provider Identifier (NPI) number assigned to this provider is 1285180331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Nadine Daou, NP-C has received a total of $2,716 in payments from pharmaceutical and medical device companies, with $701.17 received in 2024. These payments were reported across 173 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($2,683).
As a Medicare-enrolled provider, Daou has provided services to 1,394 Medicare beneficiaries, totaling 8,630 services with total Medicare billing of $232,488. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Location Newburyport, MA
- Active Since 08/29/2016
- Last Updated 06/16/2021
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1285180331
Products in Payments
- JARDIANCE (Drug) $320.22
- Ozempic (Drug) $226.89
- EVENITY (Biological) $183.00
- Rybelsus (Drug) $162.52
- FARXIGA (Drug) $159.86
- Kerendia (Drug) $143.92
- TEPEZZA (Drug) $97.72
- LYUMJEV (Drug) $90.69
- MOUNJARO (Drug) $83.52
- SYNTHROID (Drug) $72.14
- TRULICITY (Drug) $62.88
- SOLIQUA 100/33 (Biological) $59.15
- Repatha (Biological) $54.05
- AFREZZA (Drug) $48.11
- TZIELD (Biological) $46.96
- RECORLEV (Drug) $46.26
- t:slim X2 Insulin Pump with Control-IQ (Device) $45.48
- CeQur Simplicity (Device) $45.12
- RYBELSUS (Drug) $44.51
- SYNJARDY (Drug) $44.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Newburyport
Cooper Paul, Fnp, FNP
Nurse Practitioner — Payments: $1,593
Nurse Practitioner $1,593
Mrs. Tracy Wilbraham, Np, NP
Nurse Practitioner — Payments: $231.97
Nurse Practitioner $231.97
Teresa Reardon-Pollini
Nurse Practitioner — Payments: $186.74
Nurse Practitioner $186.74
Matthew Johnson, Np, NP
Nurse Practitioner — Payments: $67.47
Nurse Practitioner $67.47
Katherine Clifford, N.p, N.P
Nurse Practitioner — Payments: $14.68
Nurse Practitioner $14.68
Margaret White-Guthro, N.p, N.P
Nurse Practitioner
Nurse Practitioner